Paclitaxel remains first-line for cutaneous angiosarcoma, but absence of validated second-line therapy creates a major unmet need after progression or intolerance. A 30-patient, 15-center JCOG study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results